Literature DB >> 24722670

Conformational stability as a design target to control protein aggregation.

Joseph A Costanzo1, Christopher J O'Brien, Kathryn Tiller, Erin Tamargo, Anne Skaja Robinson, Christopher J Roberts, Erik J Fernandez.   

Abstract

Non-native protein aggregation is a prevalent problem occurring in many biotechnological manufacturing processes and can compromise the biological activity of the target molecule or induce an undesired immune response. Additionally, some non-native aggregation mechanisms lead to amyloid fibril formation, which can be associated with debilitating diseases. For natively folded proteins, partial or complete unfolding is often required to populate aggregation-prone conformational states, and therefore one proposed strategy to mitigate aggregation is to increase the free energy for unfolding (ΔGunf) prior to aggregation. A computational design approach was tested using human γD crystallin (γD-crys) as a model multi-domain protein. Two mutational strategies were tested for their ability to reduce/increase aggregation rates by increasing/decreasing ΔGunf: stabilizing the less stable domain and stabilizing the domain-domain interface. The computational protein design algorithm, RosettaDesign, was implemented to identify point variants. The results showed that although the predicted free energies were only weakly correlated with the experimental ΔGunf values, increased/decreased aggregation rates for γD-crys correlated reasonably well with decreases/increases in experimental ΔGunf, illustrating improved conformational stability as a possible design target to mitigate aggregation. However, the results also illustrate that conformational stability is not the sole design factor controlling aggregation rates of natively folded proteins.

Entities:  

Keywords:  computational protein design; protein aggregation; protein engineering; protein folding

Mesh:

Substances:

Year:  2014        PMID: 24722670     DOI: 10.1093/protein/gzu008

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  7 in total

1.  Boosting antibody developability through rational sequence optimization.

Authors:  Daniel Seeliger; Patrick Schulz; Tobias Litzenburger; Julia Spitz; Stefan Hoerer; Michaela Blech; Barbara Enenkel; Joey M Studts; Patrick Garidel; Anne R Karow
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Modulating non-native aggregation and electrostatic protein-protein interactions with computationally designed single-point mutations.

Authors:  C J O'Brien; M A Blanco; J A Costanzo; M Enterline; E J Fernandez; A S Robinson; C J Roberts
Journal:  Protein Eng Des Sel       Date:  2016-05-09       Impact factor: 1.650

3.  Directed evolution of glycosyltransferase for enhanced efficiency of avermectin glucosylation.

Authors:  Ha-Young Choi; Hyun Seung Lim; Kwang-Hyun Park; Junheon Kim; Won-Gon Kim
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-27       Impact factor: 4.813

4.  A single freeze-thawing cycle for highly efficient solubilization of inclusion body proteins and its refolding into bioactive form.

Authors:  Xingmei Qi; Yifan Sun; Sidong Xiong
Journal:  Microb Cell Fact       Date:  2015-02-22       Impact factor: 5.328

5.  Mutational probing of protein aggregates to design aggregation-resistant proteins.

Authors:  Mohamad Zahid Kamal; Virender Kumar; Kundarapu Satyamurthi; Kushal Kumar Das; Nalam Madhusudhana Rao
Journal:  FEBS Open Bio       Date:  2016-01-04       Impact factor: 2.693

6.  Role of anisotropic interactions for proteins and patchy nanoparticles.

Authors:  Christopher J Roberts; Marco A Blanco
Journal:  J Phys Chem B       Date:  2014-10-24       Impact factor: 2.991

7.  An accelerated surface-mediated stress assay of antibody instability for developability studies.

Authors:  Marie R G Kopp; Adriana-Michelle Wolf Pérez; Marta Virginia Zucca; Umberto Capasso Palmiero; Brigitte Friedrichsen; Nikolai Lorenzen; Paolo Arosio
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.